Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06171789 · ClinicalTrials.gov registry record · Phase 1
PRO1107 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT06171789 is a Phase 1 study that was terminated before completion, run by Genmab. The registered enrollment target is 33 participants.
The verdict
NCT06171789, a Phase 1 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
Interventions
- DRUG GEN1107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2025-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06171789
The ClinicalTrials.gov registry entry for NCT06171789 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GEN1107 is the first listed.
NCT06171789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06171789 about?
NCT06171789 is a clinical study titled "PRO1107 in Patients With Advanced Solid Tumors". This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B:...
What is the current status of trial NCT06171789?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2024-01-03. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT06171789?
The interventions under investigation include: GEN1107 (DRUG).
Who is sponsoring clinical trial NCT06171789?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.